The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Marion Merrell Dow, Inc., Marion Park Drive, P.O. Box 9627, Kansas City, Missouri 64134-0627, has filed an application requesting conditional approval for the export of the human drug Anzemet (dolasetron mesilate) Tablets to France for packaging and transshipment to the United Kingdom. Anzemet is used for the treatment of nausea and vomiting induced by cancer chemotherapy, radiotherapy and postoperative nausea and vomiting. The application was received and filed in the Center for Drug Evaluation and Research on August 8, 1995, which shall be considered the filing date for purposes of the act.
Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
The agency encourages any person who submits relevant information on the application to do so by September 5, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period. (1) exclude himself from serving in any advisory capacity to the PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (2) certify in every PHS research application or report that all contributors to the application or report are properly cited or otherwise acknowledged. This certification must be endorsed by an institutional official, and the institution must send a copy of the certification to ORI.
FOR FURTHER INFORMATION CONTACT:
Director In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the National Institutes of Health (NIH), National Cancer Institute (NCI) will publish periodic summaries of proposed projects. To request more information on the proposed project, call Shelia Hoar Zahm, Sc.D., Epidemiologist, at (301) 496-9093. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including
